ATE389648T1 - 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten - Google Patents

4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten

Info

Publication number
ATE389648T1
ATE389648T1 AT00904889T AT00904889T ATE389648T1 AT E389648 T1 ATE389648 T1 AT E389648T1 AT 00904889 T AT00904889 T AT 00904889T AT 00904889 T AT00904889 T AT 00904889T AT E389648 T1 ATE389648 T1 AT E389648T1
Authority
AT
Austria
Prior art keywords
heterocyclylsulfonamido
pyridylpyrimidines
methoxyphenoxy
methoxy
phenyl
Prior art date
Application number
AT00904889T
Other languages
English (en)
Inventor
Volker Breu
Philippe Coassolo
Rolf Huber
Werner Neidhart
Henri Ramuz
Sebastien Roux
Hans Wessel
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Application granted granted Critical
Publication of ATE389648T1 publication Critical patent/ATE389648T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Neurosurgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyridine Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
AT00904889T 1999-01-18 2000-01-10 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten ATE389648T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP99100784 1999-01-18

Publications (1)

Publication Number Publication Date
ATE389648T1 true ATE389648T1 (de) 2008-04-15

Family

ID=8237359

Family Applications (1)

Application Number Title Priority Date Filing Date
AT00904889T ATE389648T1 (de) 1999-01-18 2000-01-10 4-(heterocyclylsulfonamido)-5-methoxy-6-(2- methoxyphenoxy)-2-phenyl- oder pyridylpyrimidine als endothelinrezeptorantagonisten

Country Status (31)

Country Link
US (1) US6242601B1 (de)
EP (1) EP1149091B1 (de)
JP (1) JP3983477B2 (de)
KR (1) KR100478797B1 (de)
CN (1) CN1340049A (de)
AR (1) AR029879A1 (de)
AT (1) ATE389648T1 (de)
AU (1) AU763112B2 (de)
BR (1) BR0007595A (de)
CA (1) CA2359363C (de)
CO (1) CO5150187A1 (de)
CZ (1) CZ20012546A3 (de)
DE (1) DE60038365D1 (de)
ES (1) ES2301476T3 (de)
GC (1) GC0000248A (de)
HR (1) HRP20010515A2 (de)
HU (1) HUP0200021A3 (de)
IL (2) IL144055A0 (de)
MA (1) MA27124A1 (de)
MY (1) MY121136A (de)
NO (1) NO322800B1 (de)
NZ (1) NZ512662A (de)
PE (1) PE20001421A1 (de)
PL (1) PL350093A1 (de)
RU (1) RU2224757C2 (de)
TR (1) TR200102071T2 (de)
TW (1) TWI284642B (de)
UY (1) UY25904A1 (de)
WO (1) WO2000042035A1 (de)
YU (1) YU50001A (de)
ZA (1) ZA200105279B (de)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7329670B1 (en) 1997-12-22 2008-02-12 Bayer Pharmaceuticals Corporation Inhibition of RAF kinase using aryl and heteroaryl substituted heterocyclic ureas
US7517880B2 (en) 1997-12-22 2009-04-14 Bayer Pharmaceuticals Corporation Inhibition of p38 kinase using symmetrical and unsymmetrical diphenyl ureas
US20080300281A1 (en) * 1997-12-22 2008-12-04 Jacques Dumas Inhibition of p38 Kinase Activity Using Aryl and Heteroaryl Substituted Heterocyclic Ureas
US20080269265A1 (en) * 1998-12-22 2008-10-30 Scott Miller Inhibition Of Raf Kinase Using Symmetrical And Unsymmetrical Substituted Diphenyl Ureas
EP1140840B1 (de) * 1999-01-13 2006-03-22 Bayer Pharmaceuticals Corp. -g(v)-carboxyaryl substituierte diphenyl harnstoffe als raf kinase inhibitoren
US7928239B2 (en) 1999-01-13 2011-04-19 Bayer Healthcare Llc Inhibition of RAF kinase using quinolyl, isoquinolyl or pyridyl ureas
US8124630B2 (en) 1999-01-13 2012-02-28 Bayer Healthcare Llc ω-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7351834B1 (en) 1999-01-13 2008-04-01 Bayer Pharmaceuticals Corporation ω-Carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
EP2298311B1 (de) * 1999-01-13 2012-05-09 Bayer HealthCare LLC Omega-carboxyarylsubstituierte-Diphenyl-Harnstoffe als p38-Kinasehemmer
US6417360B1 (en) * 1999-03-03 2002-07-09 Hoffmann-La Roche Inc. Heterocyclic sulfonamides
MY140724A (en) 2000-07-21 2010-01-15 Actelion Pharmaceuticals Ltd Novel arylethene-sulfonamides
EP1693372A1 (de) 2000-12-18 2006-08-23 Actelion Pharmaceuticals Ltd. Neue Sulfamiden und deren Verwendung als Endothelin-Antagonisten
US7235576B1 (en) 2001-01-12 2007-06-26 Bayer Pharmaceuticals Corporation Omega-carboxyaryl substituted diphenyl ureas as raf kinase inhibitors
US7371763B2 (en) * 2001-04-20 2008-05-13 Bayer Pharmaceuticals Corporation Inhibition of raf kinase using quinolyl, isoquinolyl or pyridyl ureas
EP2305255B1 (de) * 2001-12-03 2012-08-22 Bayer HealthCare LLC Arylharnstoff-Verbindungen in Kombination mit anderen zytostatisch oder zytotoxisch wirksamen Stoffen zur Behandlungen menschlicher Krebserkrankungen
ATE529406T1 (de) 2002-02-11 2011-11-15 Bayer Healthcare Llc Aryl-harnstoffe als kinase inhibitoren
WO2003068229A1 (en) 2002-02-11 2003-08-21 Bayer Pharmaceuticals Corporation Pyridine, quinoline, and isoquinoline n-oxides as kinase inhibitors
WO2003068223A1 (en) * 2002-02-11 2003-08-21 Bayer Corporation Aryl ureas with raf kinase and angiogenesis inhibiting activity
DK1478358T3 (da) 2002-02-11 2013-10-07 Bayer Healthcare Llc Sorafenibtosylat til behandling af sygdomme kendetegnet ved unormal angiogenese
NZ540937A (en) * 2002-12-02 2008-06-30 Actelion Pharmaceuticals Ltd Pyrimidine-sulfamides and their use as endothelian receptor antagonist
US7269460B2 (en) * 2003-02-28 2007-09-11 Medtronic, Inc. Method and apparatus for evaluating and optimizing ventricular synchronization
UY28213A1 (es) * 2003-02-28 2004-09-30 Bayer Pharmaceuticals Corp Nuevos derivados de cianopiridina útiles en el tratamiento de cáncer y otros trastornos.
EP1636585B2 (de) 2003-05-20 2012-06-13 Bayer HealthCare LLC Diaryl-harnstoffe mit kinasehemmender wirkung
PL1663978T3 (pl) 2003-07-23 2008-04-30 Bayer Healthcare Llc Fluoropodstawiony omega-karboksyarylodifenylomocznik do leczenia i profilaktyki chorób i stanów
EP1595880A1 (de) * 2004-05-13 2005-11-16 Speedel Pharma AG Kristallforme eines Pyridinylsulfonamids und deren Verwendung als Endothelinrezeptorantagonisten
CR9465A (es) * 2005-03-25 2008-06-19 Surface Logix Inc Compuestos mejorados farmacocineticamente
WO2007119214A2 (en) * 2006-04-13 2007-10-25 Actelion Pharmaceuticals Ltd Endothelin receptor antagonists for early stage idiopathic pulmonary fibrosis
AU2007267209A1 (en) 2006-05-29 2007-12-06 Nicox S.A. Nitrated heterocyclic compounds as endothelin receptor antagonist
AR062501A1 (es) 2006-08-29 2008-11-12 Actelion Pharmaceuticals Ltd Composiciones terapeuticas
MX2010001837A (es) 2007-08-17 2010-03-10 Actelion Pharmaceuticals Ltd Derivados de 4-pirimidinasulfamida.
CN107108550B (zh) * 2014-11-21 2020-03-03 大金工业株式会社 新型的氟代不饱和环状碳酸酯及其制造方法
CN109260164A (zh) * 2018-10-07 2019-01-25 威海贯标信息科技有限公司 一种阿伏生坦片剂组合物
CN112778215B (zh) * 2021-01-29 2023-06-20 中国医科大学 2-甲氧基苯氧基嘧啶类抗肿瘤化合物及其制备方法和应用
CN112898208B (zh) * 2021-01-29 2023-06-20 中国医科大学 苯基嘧啶胺类抗肿瘤化合物及其制备方法和应用
EP4582086A3 (de) 2021-12-17 2025-07-23 Idorsia Pharmaceuticals Ltd Clazosentan-dinatriumsalz, dessen herstellung und pharmazeutische zusammensetzungen damit

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996016963A1 (de) * 1994-11-25 1996-06-06 F. Hoffmann-La Roche Ag Sulfonamide und deren verwendung als heilmittel
CA2162630C (en) * 1994-11-25 2007-05-01 Volker Breu Sulfonamides
US5837708A (en) 1994-11-25 1998-11-17 Hoffmann-La Roche Inc. Sulphonamides
TW313568B (de) * 1994-12-20 1997-08-21 Hoffmann La Roche
KR100456650B1 (ko) * 1995-12-20 2005-06-20 야마노우치세이야쿠 가부시키가이샤 아릴에텐설폰아미드유도체

Also Published As

Publication number Publication date
US6242601B1 (en) 2001-06-05
HUP0200021A2 (hu) 2002-05-29
YU50001A (sh) 2004-03-12
CA2359363A1 (en) 2000-07-20
KR20010094746A (ko) 2001-11-01
HRP20010515A2 (en) 2003-06-30
PL350093A1 (en) 2002-11-04
JP3983477B2 (ja) 2007-09-26
AU2663000A (en) 2000-08-01
IL144055A (en) 2007-07-24
DE60038365D1 (en) 2008-04-30
EP1149091B1 (de) 2008-03-19
KR100478797B1 (ko) 2005-03-24
JP2002534518A (ja) 2002-10-15
HUP0200021A3 (en) 2003-01-28
ES2301476T3 (es) 2008-07-01
NO322800B1 (no) 2006-12-11
RU2224757C2 (ru) 2004-02-27
UY25904A1 (es) 2001-07-31
AR029879A1 (es) 2003-07-23
ZA200105279B (en) 2002-10-07
AU763112B2 (en) 2003-07-10
CN1340049A (zh) 2002-03-13
GC0000248A (en) 2006-11-01
NO20013454D0 (no) 2001-07-12
WO2000042035A1 (en) 2000-07-20
NZ512662A (en) 2003-11-28
EP1149091A1 (de) 2001-10-31
CA2359363C (en) 2006-03-14
CO5150187A1 (es) 2002-04-29
CZ20012546A3 (cs) 2001-12-12
MA27124A1 (fr) 2005-01-03
PE20001421A1 (es) 2000-12-18
BR0007595A (pt) 2001-10-16
IL144055A0 (en) 2002-04-21
MY121136A (en) 2005-12-30
TWI284642B (en) 2007-08-01
TR200102071T2 (tr) 2002-03-21
NO20013454L (no) 2001-07-12

Similar Documents

Publication Publication Date Title
PL350093A1 (en) 4-(heterocyclylsulfonamido) -5-methoxy-6- (2-methoxyphenoxy) -2-phenyl- or pyridylpyrimidines as endothelin receptor antagonists
ATE328871T1 (de) 4-phenyl-pyridin-derivate verwendbar als neurokinin-1 rezeptor antagonisten
ATE299865T1 (de) Piperazinderivate verwendbar als ccr5 antagonisten
ATE299866T1 (de) Piperidinderivate verwendbar als ccr5 antagonisten
DE60022386D1 (de) Substituierte imidazole als neuropeptide y y5 rezeptor antagonisten
ATE263151T1 (de) Indolderivate verwendbar als endothelinrezeptorantagonisten
ATE288898T1 (de) Phenylethenyl- oder phenylethinylderivate als glutamatrezeptorantagonisten
ATE259363T1 (de) Piperazinderivate als 5-ht1b antagonisten
ATE400558T1 (de) Metabotropische glutamatrezeptor-antagonisten
DE60106607D1 (de) Substituierte 1-aminoalkyl-lactame und ihre verwendung als muscarinrezeptor antagonisten
ATE368659T1 (de) Thrombinrezeptorantagonisten
ATE296825T1 (de) 4-aminopyrrole(3,2-d)pyrimidine als neuropeptid rezeptor antagonisten
DE60114413D1 (de) Substituierte 1-aminoalkyl-lactame und deren verwendung als muscarinrezeptor-antagonisten
ATE400554T1 (de) 2-arylethyl-(piperidin-4-ylmethyl)amine derivatives als muskarin-rezeptor antagonisten
NO20015779L (no) Bradykinin-reseptorantagonister
NO20016053D0 (no) IL-8 reseptor-antagonister
NO20020644D0 (no) Nye integrinreseptor-antagonister
DE50100358D1 (de) Neue N-Triazolylmethyl-Piperazinderivate als Neurokininrezeptor-Antagonisten
DE60130000D1 (de) Zwitterionische tachykinin-rezeptor-antagonisten
ATE286018T1 (de) Biphenylderivate als neurokinin-1 antagonisten
NO20016052D0 (no) IL-8-reseptor-antagonister
DK1180028T3 (da) IL-8-receptorantagonister
NO20014224D0 (no) 4-heterocyklysulfonamidyl-6-metoksy-5-(2-metoksy-fenoksy)-2- pyridyl-pyrimidinderivater, fremstilling derav og anvendelse somendotelin reseptor antagonister
DE60113525D1 (de) Propansäure-derivate als integrin-rezeptor-antagonisten
ATE264301T1 (de) Muscarin-antagonisten

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties